Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...
-
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...
-
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
-
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
-
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
-
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to...
-
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a...
-
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) is a devastating genetic cardiac disease affecting approximately 60,000 individuals in the United States LX2020 preclinical studies demonstrated...
-
LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and...